EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

Clinical trial NCT07410676 · RECRUITING

Trial details

NCT number: NCT07410676
Sponsor: Essen Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Cancer Sarcoma Leukaemia Breast Cancer (Locally Advanced or Metastatic)Lung Cancer (Diagnosis)Colorectal Cancer Melanoma (Skin Cancer)Bladder Cancer Kidney Cancer Pancreatic Cancer Metastatic Liver Cancer (Primary and Metastatic)Ovarian Cancer

Start date: 2026-02-01
Primary completion: 2028-12-21
Enrollment: 83

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.